IP Library › Granted Patent US 12,448,380
Granted Patent B2
US 12,448,380 · App. 19/002,103 · Granted Oct 21, 2025

Positive modulators of the muscarinic acetylcholine receptor M4

Inventors: Craig W. Lindsley (Brentwood, TN); Darren W. Engers (Brentwood, TN); Kayla J. Temple (Spring Hill, TN); Alison R. Gregro (Mount Juliet, TN); Alexa E. Richardson (Nashville, TN); Madeline F. Long (Nashville, TN)
Assignee: Vanderbilt University
C07D471/04A61K31/4545C07B59/002
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,448,380
App. No.
19/002,103
Granted
Oct 21, 2025
Kind
B2
Abstract

Deuterium-labeled 4-((2,3-dihydrobenzo[b][1,4]dioxin-6-yl)oxy)piperidines substituted with pyrrolo[3,4-b]pyridin-5-one, furo[3,4-b]pyridin-5(7H)-one, or [1,2,4]triazolo[4,3-a]pyrimidin-3(2H)-one are positive allosteric modulators of the muscarinic acetylcholine receptor M 4 (mAChR M 4 ) and may have use in treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction.

Claims (9)

1. A method of treating a neurological, psychiatric, or cognitive disorder associated with the mAChR M4 receptor, comprising administering Compound 3, having the structure:

or a pharmaceutically acceptable salt thereof, to a subject in need thereof.

2. The method of claim 1 , wherein the neurological, psychiatric, or cognitive disorder associated with the mAChR M4 receptor is a neurological disorder.

3. The method of claim 2 , wherein the neurological disorder is selected from brain tumor, dementia with Lewy bodies, multiple sclerosis, sarcoidosis, Lyme disease, syphilis, Alzheimer's disease, Parkinson's disease, and anti-NMDA receptor encephalitis.

4. The method of claim 1 , wherein the neurological, psychiatric, or cognitive disorder associated with the mAChR M4 receptor is a psychiatric disorder.

5. The method of claim 4 , wherein the psychiatric disorder is selected from schizophrenia, brief psychotic disorder, schizophreniform disorder schizoaffective disorder, delusional disorder, and shared psychotic disorder.

6. The method of claim 1 , wherein the neurological, psychiatric, or cognitive disorder associated with the mAChR M4 receptor is a cognitive disorder.

7. The method of claim 6 , wherein the cognitive disorder is selected from dementia, delirium, amnestic disorder, substance-induced persisting delirium, age-related cognitive decline, and mild cognitive impairment.

8. The method of claim 4 , wherein the psychiatric disorder is schizophrenia.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 31, 2024
From: LINDSLEY, CRAIG W.; ENGERS, DARREN W.; TEMPLE, KAYLA J.; GREGRO, ALISON R.; RICHARDSON, ALEXA E.; LONG, MADELINE F.
To: VANDERBILT UNIVERSITY
Reel/Frame 069832/0049 →
Continuity (4)
Continuation 18750829 · Jun 21, 2024
Provisional Application 63610220 · Dec 14, 2023
Provisional Application 63509589 · Jun 22, 2023
Related Publication 20250122199A1 · Apr 17, 2025
References Cited (33)
US 10329289B2 · Bao et al. · 2019 [cited by applicant]
US 11884676B2 · Lindsley et al. · 2024 [cited by applicant]
WO WO2017112719A1 · 2017 [cited by applicant]
WO WO2017107087A1 · 2017 [cited by examiner]
WO WO2018112840A1 · 2018 [cited by applicant]
WO WO2018118736A1 · 2018 [cited by applicant]
WO WO2022015988A1 · 2022 [cited by examiner]
Harbeson, S. L., et al., Deuterium in Drug Discovery and Development, Annual Reports in Medicinal Chemistry, vol. 46, Chapter 24, 2011, 404-415. (Year: 2011). [cited by examiner]
U.S. Appl. No. 19/002,083, filed Dec. 26, 2024, Lindsley et al. [cited by applicant]
U.S. Appl. No. 19/002,334, filed Dec. 26, 2024, Lindsley et al. [cited by applicant]
U.S. Appl. No. 19/002,355, filed Dec. 26, 2024, Lindsley et al. [cited by applicant]
“1,2-Dibromoethane-D4 (D, 99%), Safety Data Sheet,” Cambridge Isotope Laboratories, Inc., 2017, Version 3.0, 10 pages. [cited by applicant]
Ao et al., “Synthesis of deuterium-labeled crizotinib, a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK),” Journal of Labelled Compound… [cited by applicant]
Bodick et al., “Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease,” Archives of Neurology, 1997, 54(4):465-473. [cited by applicant]
Bubser et al., “Selective activation of M4 muscarinic acetylcholine receptors reverses MK-801-induced behavioral impairments and enhances associative learning in rodents,” ACS Chemical Neuroscience, 2014, 5(10):920-942. [cited by applicant]
Bymaster et al., “Potential role of muscarinic receptors in schizophrenia, ” Life sciences, 1999, 64(6-7):527-534. [cited by applicant]
Bymaster et al., “Unexpected anti psychotic-like activity with the muscarinic receptor ligand (5R, 6R) 6-(3-3 propylthio-1, 2, 5-thiadiazol-4-yl)-1-azabicyclo [3.2.1] octane,” European Journal of Pharmacology, 1998, 356… [cited by applicant]
CAS No. 22581-63-1, “1,2-Dibromoethane-d4,” Sigma-Aldrich, retrieved on Jan. 16, 2025, retrieved from URL<https://www.sigmaaldrich.com/US/en/product/aldrich/425362>, 9 pages. [cited by applicant]
CAS No. 530-62-1, “1,1′-Carbonyldiimidazole,” Sigma-Aldrich, retrieved on Jan. 16, 2025, retrieved from URL<https://www.sigmaaldrich.com/US/en/product/mm/802301>, 9 pages. [cited by applicant]
CAS No. 937-14-4, “3-Chloroperbenzoic acid,” Sigma-Aldrich, retrieved on Jan. 16, 2025, retrieved from URL<https://www.sigmaaldrich.com/US/en/product/aldrich/273031>, 12 pages. [cited by applicant]
Conde-Ceide et al., “Discovery of VU0409551/JNJ-46778212: An mGlu5 positive allosteric modulator clinical candidate targeting schizophrenia,” ACS Medicinal Chemistry Letters, 2015, 6(6):716-720. [cited by applicant]
Felts et al., “Discovery of N-(5-fluoropyridin-2-yl)-6-methyl-4-(pyrimidin-5-yloxy) picolinamide (VU0424238): a novel negative allosteric modulator of metabotropic glutamate receptor subtype 5 selected for clinical eval… [cited by applicant]
Garrison et al., “Development of VU6019650: a potent, highly selective, and systemically active orthosteric antagonist of the M5 muscarinic acetylcholine receptor for the treatment of opioid use disorder,” Journal of Me… [cited by applicant]
Gleason et al., “Deuterium: Natural Variations Used as a Biological Tracer,” Science, 1970, 169:1085-1086. [cited by applicant]
Harbeson et al., “Chapter 24: Deuterium in Drug Discovery and Development,” Annual Reports in Medicinal Chemistry, 2011, 46:404-417. [cited by applicant]
International Search Report and Written Opinion in International Appln. No. PCT/US2024/035078, mailed on Oct. 8, 2024, 12 pages. [cited by applicant]
Johnson et al., “Drug Design Targeting the Muscarinic Receptors and the Implications in Central Nervous System Disorders,” BioMedicines, 2022, 10(398):1-36. [cited by applicant]
Morris et al., “Discovery of (S)-2-Cyclopentyl-N-((1-Isopropylpyrrolidin2-Y1)-9- Methyl-1-Oxo-2, 9-Dihydro-1 H-Pyrrido [3, 4-b] Indole-4-Carboxamide (VU0453379): a novel, CNS penetrant glucagon-like peptide 1 receptor (… [cited by applicant]
Shannon et al., “Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats, ” Journal of Pharmacology and Experimental Therapeutics, 1999, 290(2):901-… [cited by applicant]
Shannon et al., “Xanomeline, an M1/M4 preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice,” Schizophrenia Research, 2000, 42(3):249-259. [cited by applicant]
Spock et al., “Discovery of VU6028418: A Highly Selective and Orally Bioavailable M4 Muscarinic Acetylcholine Receptor Antagonist,” ACS Medicinal Chemistry Letters, 2021, 12:1342-1349. [cited by applicant]
Stanhope et al., “The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat,” The Journal of Pharmacology and Experimental Therapeutics, 2001, 299(2):782-792. [cited by applicant]
Yu et al., “Discovery of ethyl ketone-based highly selective HDACs 1, 2, 3 inhibitors for HIV latency reactivation with minimum cellular potency serum shift and reduced hERG activity,” Journal of Medicinal Chemistry, 20… [cited by applicant]